Omeros, Fagron deal

Omeros granted Fagron exclusive rights to commercialize OMS103 in the U.S. Fagron will pay Omeros a majority share of gross revenue from sales plus a minimum revenue per vial sold. Omeros is eligible for up to $10 million in commercial milestones. ...